What the ClinicalTrials.gov update actually says

The registry entry for NCT05929066 — Eli Lilly's phase 3 evaluation of retatrutide (development code LY3437943) in adults with obesity or overweight — was refreshed on August 21, 2026 and now shows an overall status of COMPLETED. The record lists an enrollment of 2,335 participants and names Eli Lilly and Company as the sponsor. It is the largest retatrutide trial visible in the public registry.

Per the registry description, the trial was organized as a master protocol carrying the internal designation J1I-MC-GZBJ. Rather than running as a single homogeneous cohort, it folded in defined subsets: participants who also had knee osteoarthritis, tracked under J1I-MC-GOA1, and participants with obstructive sleep apnea, tracked under J1I-MC-GSA1. The stated purpose was to evaluate both efficacy and safety in those populations.

The record also describes the study's length and structure. It was designed to run about 89 weeks and include up to 24 clinic visits. An optional second addendum was made available to roughly 500 participants, allowing them to continue receiving retatrutide for up to an additional 24 weeks beyond the main protocol.

What is retatrutide, and how does it differ from semaglutide and tirzepatide?

Retatrutide is an investigational injectable metabolic drug from Eli Lilly. Lilly has described it as a single molecule designed to act at three receptors at once: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. That third target is what separates it from the drugs already on the market.

For comparison, semaglutide — sold by Novo Nordisk as Ozempic and Wegovy — acts at the GLP-1 receptor alone. Tirzepatide, Lilly's Mounjaro and Zepbound, acts at both the GIP and GLP-1 receptors. Adding glucagon receptor activity is the pharmacological bet behind retatrutide: glucagon signaling is associated with energy expenditure and hepatic fat handling, which is why retatrutide has drawn attention beyond weight alone.

None of that is settled by a registry status change. Mechanistic rationale is not evidence of outcome, and the claims about what three-receptor activity delivers in humans belong to the trial data, which is not yet public for this study.

For readers already tracking an investigational protocol under provider direction, the retatrutide dosage calculator handles the arithmetic of concentration and syringe units without touching the question of what belongs in a protocol.

The agency also maintains a dedicated page for coordination with state regulators, describing how it shares inspection findings, complaints, and adverse event information about compounders whose practices it considers risky.

Why the osteoarthritis and sleep apnea subsets matter

The inclusion of knee osteoarthritis and obstructive sleep apnea cohorts inside the master protocol is a strategic detail worth noticing. Both conditions are strongly associated with obesity, and both have already been used by Lilly as separate approval pathways for tirzepatide. Regulators generally require condition-specific evidence before a drug's label can name a condition, which is why these subsets exist as distinct sub-studies rather than as post-hoc slices of a single dataset.

For readers tracking the field, that structure suggests Lilly is building a portfolio of indications for retatrutide from the start rather than pursuing weight reduction alone and expanding later. It also means any eventual publication or results posting may arrive as several analyses rather than one headline number.

The registry does not state what endpoints were measured in each subset beyond the general purpose of evaluating efficacy and safety, and no findings have been posted.

Trials of incretin-class drugs almost always build in a stepwise escalation phase, so it helps to know what titration means before reading the eventual results.

Does a completed trial mean retatrutide is close to approval?

No. On ClinicalTrials.gov, a status of completed means the study finished as planned — the last participant completed the last visit — and nothing more. It is not a results posting, not a regulatory submission, and not an approval. Sponsors are required to post summary results to the registry within a set window after completion for many applicable trials, but that window has not closed here and the record currently shows no outcome data.

Between a completed phase 3 trial and a marketed medicine sit several distinct steps: database lock and analysis, publication or conference presentation, a new drug application filed with the U.S. Food and Drug Administration, agency review, and a decision. Each of those can take months, and each can change the picture. A drug can complete phase 3 and still fail to reach the market.

Anyone reading a completion status as a signal about timelines is reading more into the registry than the registry says. The useful takeaway is narrower: the data now exists, and at some point it will become visible.

When a drug class is still accumulating safety evidence, consistent side-effect logging is what turns a vague recollection into something a provider can actually act on.

Because retatrutide is unapproved, there is no pharmacy version of it. That distinction matters more for this drug than for semaglutide or tirzepatide, both of which have been the subject of extensive compounding activity. U.S. compounding law is built around approved drugs and specific eligible bulk substances, and the FDA's own explainer on human drug compounding frames compounding as the preparation of a medication tailored to an identified individual patient's needs — not as a route to distribute an investigational molecule.

In practice, material sold online under the retatrutide name is research-chemical supply that sits outside any pharmacy oversight, with no independent guarantee of identity, purity, sterility, or concentration. The FDA has repeatedly said it shares information with state regulators about compounders whose practices it considers risky, and it maintains a dedicated page for that state coordination.

This is not a comment on what anyone should do. It is a description of what the regulatory record says exists and does not exist, which is context a registry headline about a completed phase 3 trial does not supply on its own.

According to the ClinicalTrials.gov record for NCT05929066, the study enrolled 2,335 participants, was sponsored by Eli Lilly and Company, and is now listed with a status of completed.

Other registry updates in the same batch

The retatrutide record was not the only relevant entry refreshed on August 21. A phase 4 Lilly study of tirzepatide in 344 adults in India with type 2 diabetes or with obesity or overweight, registered as NCT07438444, is listed as active and no longer recruiting, with participation running about 46 weeks. Phase 4 trials run after approval and typically address safety and effectiveness in populations or settings not fully covered by the original program.

Separately, Novo Nordisk's phase 3 placebo-controlled study of oral semaglutide in children and adolescents with type 2 diabetes, NCT04596631, is listed as completed with 132 participants after roughly 66 weeks. Pediatric data of this kind is one of the routes by which a label's age range can eventually widen, though again, completion is not a result.

The FDA's questions-and-answers page on human drug compounding describes compounding as creating a medication tailored to the needs of an individual patient, a framework built around approved drugs rather than investigational molecules. the FDA's questions-and-answers page on human drug compounding.